Last reviewed · How we verify

RSVPreF3 OA vaccine

GlaxoSmithKline · Phase 3 active Biologic

RSVPreF3 OA vaccine is a Recombinant protein vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Prevention of respiratory syncytial virus (RSV) disease in older adults (≥60 years), Prevention of RSV disease in infants via maternal immunization (under investigation).

RSVPreF3 OA is a recombinant protein vaccine that presents a stabilized prefusion form of the respiratory syncytial virus (RSV) F glycoprotein to elicit protective immune responses against RSV infection.

RSVPreF3 OA is a recombinant protein vaccine that presents a stabilized prefusion form of the respiratory syncytial virus (RSV) F glycoprotein to elicit protective immune responses against RSV infection. Used for Prevention of respiratory syncytial virus (RSV) disease in older adults (≥60 years), Prevention of RSV disease in infants via maternal immunization (under investigation).

At a glance

Generic nameRSVPreF3 OA vaccine
SponsorGlaxoSmithKline
Drug classRecombinant protein vaccine
TargetRSV F glycoprotein (prefusion conformation)
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhasePhase 3

Mechanism of action

The vaccine uses a rationally designed prefusion-stabilized RSV F protein (PreF3) formulated with an oil-in-water adjuvant (OA) to enhance immunogenicity. This design aims to induce robust antibody and T-cell responses that neutralize RSV and prevent infection or severe disease. The prefusion conformation is believed to be more immunogenic and closer to the native viral structure than postfusion forms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about RSVPreF3 OA vaccine

What is RSVPreF3 OA vaccine?

RSVPreF3 OA vaccine is a Recombinant protein vaccine drug developed by GlaxoSmithKline, indicated for Prevention of respiratory syncytial virus (RSV) disease in older adults (≥60 years), Prevention of RSV disease in infants via maternal immunization (under investigation).

How does RSVPreF3 OA vaccine work?

RSVPreF3 OA is a recombinant protein vaccine that presents a stabilized prefusion form of the respiratory syncytial virus (RSV) F glycoprotein to elicit protective immune responses against RSV infection.

What is RSVPreF3 OA vaccine used for?

RSVPreF3 OA vaccine is indicated for Prevention of respiratory syncytial virus (RSV) disease in older adults (≥60 years), Prevention of RSV disease in infants via maternal immunization (under investigation).

Who makes RSVPreF3 OA vaccine?

RSVPreF3 OA vaccine is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What drug class is RSVPreF3 OA vaccine in?

RSVPreF3 OA vaccine belongs to the Recombinant protein vaccine class. See all Recombinant protein vaccine drugs at /class/recombinant-protein-vaccine.

What development phase is RSVPreF3 OA vaccine in?

RSVPreF3 OA vaccine is in Phase 3.

What are the side effects of RSVPreF3 OA vaccine?

Common side effects of RSVPreF3 OA vaccine include Injection site pain, Injection site erythema, Myalgia, Fatigue, Headache.

What does RSVPreF3 OA vaccine target?

RSVPreF3 OA vaccine targets RSV F glycoprotein (prefusion conformation) and is a Recombinant protein vaccine.

Related